Plus Therapeutics' CNSide Assay Gains National Coverage with Elevance Health, Reaching 126 Million Lives
Summary
Plus Therapeutics has secured a national coverage agreement with Elevance Health for its CNSide® Cerebrospinal Fluid Assay, effective May 1, 2026. This expands coverage by 45.4 million people, bringing the total contracted coverage for CNSide to 126 million lives. This is a highly significant commercial milestone for the company, following its Medicare enrollment approval in May, and substantially increases the market access and revenue potential for its key diagnostic product for metastatic CNS cancer. For a company of Plus Therapeutics' size, this agreement with a major insurer is a critical step towards commercial viability and generating substantial revenue.
At the time of this announcement, PSTV was trading at $3.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.3M. The 52-week trading range was $2.90 to $23.43. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.